水虫治療薬市場-世界の産業規模、シェア、動向、機会、予測、タイプ別、製品タイプ別、薬剤クラス別、流通チャネル別、地域別、競合別、2020年～2030年

水虫治療薬の世界市場は、2024年に9億6,534万米ドルと評価され、2030年までには13億1,026万米ドルに達すると予測され、予測期間中にCAGR5.22％で成長すると予測されています。

水虫（足白癬）の医薬品治療に焦点を当てたこの市場は、主に足にかゆみ、発赤、皮膚の鱗屑を引き起こす広範な真菌感染症に対処します。水虫が生活の質に与える影響に対する認識が高まり、迅速かつ効果的な治療オプションに対する需要が高まっています。罹患者には、スポーツ選手、免疫力が低下している人、ジムや水泳場など湿気の多い環境に頻繁にさらされる人などが含まれます。世界人口の約15％が真菌感染症に罹患していることから、利用しやすく効果的な治療法の必要性は明らかです。市場には、市販の外用剤から処方箋が必要な強力な薬剤まで、さまざまな治療選択肢があります。製薬会社は、新規治療法の導入やドラッグデリバリー機構の改良のため、研究開発への投資を続けています。現在、北米と欧州が医療インフラと認知度の向上によりリードしている一方、アジア太平洋とラテンアメリカ地域では、医療アクセスの改善と個人の衛生意識の高まりにより成長が加速しています。

主要な市場促進要因

水虫の流行

主要市場の課題

抗真菌薬に対する耐性

主要市場動向

併用療法

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の水虫治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（足指ウェブ感染症、モカシン型感染症、潰瘍性感染症）
  • 製品タイプ別（外用クリーム・軟膏、スプレー、ローション、経口薬、その他）
  • 薬剤クラス別（抗真菌剤、コルチコステロイド、抗生物質、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024年）
• 市場マップ
  • タイプ別
  • 製品タイプ別
  • 薬剤クラス別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋の水虫治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 製品タイプ別
  • 薬剤クラス別
  • 流通チャネル別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の水虫治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の水虫治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の水虫治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの水虫治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の水虫治療薬市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Novartis AG
• Vibcare Pharma Pvt. Ltd.
• Bayer AG
• Taro Pharmaceutical Industries Ltd
• GLENMARK PHARMACEUTICALS LTD
• Abigail Healthcare Pharmaceutical
• ANI Pharmaceuticals, Inc.
• Perrigo Company plc
• Xiromed
• Sebela Pharmaceuticals

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Athlete's Foot Drugs Market was valued at USD 965.34 Million in 2024 and is projected to reach USD 1310.26 Million by 2030, growing at a CAGR of 5.22% during the forecast period. This market, which focuses on pharmaceutical treatments for athlete's foot (tinea pedis), addresses a widespread fungal infection that causes itching, redness, and skin scaling, primarily on the feet. Increased awareness of the condition's impact on quality of life has contributed to a growing demand for rapid and effective treatment options. Affected populations include athletes, individuals with compromised immunity, and those frequently exposed to moist environments such as communal gyms or swimming areas. With approximately 15% of the global population experiencing fungal infections, the need for accessible and efficacious therapies is apparent. The market includes a variety of treatment options, ranging from over-the-counter topical formulations to prescription-strength medications. Pharmaceutical companies continue to invest in research and development to introduce novel therapies and improve drug delivery mechanisms. While North America and Europe currently lead due to better healthcare infrastructure and awareness, the Asia-Pacific and Latin American regions are experiencing accelerated growth driven by improving healthcare access and rising personal hygiene consciousness.

Key Market Drivers

Prevalence of Athlete's Foot

The widespread occurrence of athlete's foot continues to be a primary factor fueling market expansion. This contagious fungal condition is frequently encountered in shared public environments, such as locker rooms and pools, and is especially prevalent among athletes and workers exposed to persistent moisture. The high transmission rate and discomfort associated with the condition compel affected individuals to seek pharmaceutical interventions. As the global incidence of tinea pedis remains elevated, the demand for antifungal treatments sustains the growth momentum of the athlete's foot drug market.

Key Market Challenges

Resistance to Antifungal Medications

A significant challenge facing the Global Athlete's Foot Drugs Market is the increasing resistance to antifungal medications. Repeated and sometimes inappropriate use of antifungal agents can result in reduced drug efficacy as fungal strains adapt and become more resilient. This not only compromises treatment outcomes but also increases the risk of prolonged infections and patient dissatisfaction. Continued use of ineffective treatments due to resistance can diminish consumer confidence in available products and hinder market progress. Addressing this challenge requires the development of innovative therapies with broader and more durable efficacy profiles.

Key Market Trends

Combination Therapies

Combination therapies have gained traction as a promising approach to managing athlete's foot. These treatments utilize multiple antifungal agents with distinct mechanisms of action to enhance therapeutic outcomes and reduce the risk of resistance. Particularly effective in persistent or recurring cases, combination therapies have shown faster symptom relief and higher eradication rates. Their adaptability allows for personalized treatment strategies tailored to the severity of individual cases. Pharmaceutical companies have responded by developing diverse combination formulations, expanding therapeutic options and reinforcing market growth through innovation and improved patient satisfaction.

Key Market Players

• Novartis AG
• Vibcare Pharma Pvt. Ltd.
• Bayer AG
• Taro Pharmaceutical Industries Ltd
• Glenmark Pharmaceuticals Ltd.
• Abigail Healthcare Pharmaceutical
• ANI Pharmaceuticals, Inc.
• Perrigo Company plc
• Xiromed
• Sebela Pharmaceuticals

Report Scope:

In this report, the Global Athlete's Foot Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Athlete's Foot Drugs Market, By Type:

• Toe Web Infection
• Moccasin-type Infection
• Ulcerative Infection

Athlete's Foot Drugs Market, By Product Type:

• Topical Creams and Ointments
• Sprays
• Lotions
• Oral Medications
• Others

Athlete's Foot Drugs Market, By Drug Class:

• Antifungal Agents
• Corticosteroid
• Antibiotics
• Others

Athlete's Foot Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Athlete's Foot Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Athlete's Foot Drugs Market.

Available Customizations:

Global Athlete's Foot Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Athlete's Foot Drugs Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Toe Web Infection, Moccasin-type Infection, Ulcerative Infection)
  • 4.2.2. By Product Type (Topical Creams and Ointments, Sprays, Lotions, Oral Medications, Others)
  • 4.2.3. By Drug Class (Antifungal Agents, Corticosteroid, Antibiotics, Others)
  • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Product Type
  • 4.3.3. By Drug Class
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Athlete's Foot Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Product Type
  • 5.2.3. By Drug Class
  • 5.2.4. By Distribution Channel
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Athlete's Foot Drugs Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Product Type
      • 5.3.1.2.3. By Drug Class
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Athlete's Foot Drugs Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Product Type
      • 5.3.2.2.3. By Drug Class
      • 5.3.2.2.4. By Distribution Channel
  • 5.3.3. Australia Athlete's Foot Drugs Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Product Type
      • 5.3.3.2.3. By Drug Class
      • 5.3.3.2.4. By Distribution Channel
  • 5.3.4. Japan Athlete's Foot Drugs Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Product Type
      • 5.3.4.2.3. By Drug Class
      • 5.3.4.2.4. By Distribution Channel
  • 5.3.5. South Korea Athlete's Foot Drugs Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Product Type
      • 5.3.5.2.3. By Drug Class
      • 5.3.5.2.4. By Distribution Channel

6. Europe Athlete's Foot Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product Type
  • 6.2.3. By Drug Class
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Athlete's Foot Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product Type
      • 6.3.1.2.3. By Drug Class
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Germany Athlete's Foot Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product Type
      • 6.3.2.2.3. By Drug Class
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Spain Athlete's Foot Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product Type
      • 6.3.3.2.3. By Drug Class
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Italy Athlete's Foot Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Product Type
      • 6.3.4.2.3. By Drug Class
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. United Kingdom Athlete's Foot Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Product Type
      • 6.3.5.2.3. By Drug Class
      • 6.3.5.2.4. By Distribution Channel

7. North America Athlete's Foot Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product Type
  • 7.2.3. By Drug Class
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Athlete's Foot Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By Drug Class
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Mexico Athlete's Foot Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By Drug Class
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Canada Athlete's Foot Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By Drug Class
      • 7.3.3.2.4. By Distribution Channel

8. South America Athlete's Foot Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product Type
  • 8.2.3. By Drug Class
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Athlete's Foot Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By Drug Class
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Argentina Athlete's Foot Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By Drug Class
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Colombia Athlete's Foot Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By Drug Class
      • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Athlete's Foot Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product Type
  • 9.2.3. By Drug Class
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Athlete's Foot Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By Drug Class
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Saudi Arabia Athlete's Foot Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Drug Class
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. UAE Athlete's Foot Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By Drug Class
      • 9.3.3.2.4. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Athlete's Foot Drugs Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Novartis AG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Vibcare Pharma Pvt. Ltd.
• 14.3. Bayer AG
• 14.4. Taro Pharmaceutical Industries Ltd
• 14.5. GLENMARK PHARMACEUTICALS LTD
• 14.6. Abigail Healthcare Pharmaceutical
• 14.7. ANI Pharmaceuticals, Inc.
• 14.8. Perrigo Company plc
• 14.9. Xiromed
• 14.10. Sebela Pharmaceuticals

15. Strategic Recommendations

16. About Us & Disclaimer